Back to top

Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viking Therapeutics yesterday and set a price target of $118.00. Thomas Smith has ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viking Therapeutics, Inc. (VKTX)